ArticleBrain and behavior2025
Exploring the Causal Links Between 338 Cerebrospinal Fluid Metabolites and Parkinson's Disease.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Causal Links Between 338 Cerebrospinal Fluid Metabolites and Parkinson's Disease.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is a progressive neurodegenerative condition characterized by motor impairments and intricate pathophysiological mechanisms. Although cerebrospinal fluid (CSF) metabolites are viewed as potential biomarkers, the primarily observational design of the majority of existing studies limits the ability to draw causal conclusions.
objectiveThe purpose of this research was to explore the causal link between CSF metabolites and PD by employing two-sample Mendelian randomization (TSMR).
methodsData on CSF metabolites were acquired from the two longitudinal cohort studies. Information regarding PD was gathered from the International Parkinson's Disease Genomics Consortium. Instrumental variables (IVs) for 338 CSF metabolites were identified based on notable SNPs. Causal impacts were assessed using Mendelian randomization techniques including inverse variance weighted (IVW) analysis and MR-Egger regression. The analyses included sensitivity assessments to evaluate issues related to heterogeneity and pleiotropy.
resultsSignificant causal associations were found between several CSF metabolites and PD. Higher levels of glycerophosphoinositol, sphingomyelin, and oxalate were linked to increased PD risk, while elevated caffeine levels appeared protective. After FDR correction, glycerophosphoinositol, oxalate, and caffeine remained significant. Sensitivity analyses confirmed robustness with no heterogeneity or pleiotropy.
conclusionThis analysis of MR reveals multiple CSF metabolites that have causal links to PD. Increased levels of glycerophosphoinositol and oxalate are associated with higher risk, whereas caffeine provide protective benefits. These metabolites may act as potential biomarkers and treatment targets for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.